Vienna-based P&F Products & Features GmbH has officially announced its acquisition of AVVie GmbH, a strategic move designed to significantly bolster its structural heart division. This transaction integrates the pioneering AngelValve™ Augmentation System, a novel transcatheter solution for mitral regurgitation, into P&F's portfolio. The acquisition reinforces P&F's long-term commitment to advancing next-generation therapies and innovating within the cardiovascular space.
Addressing a Critical Unmet Need
The acquisition directly addresses the widespread and undertreated condition of mitral regurgitation, which affects over 13 million people across Europe and the United States. A substantial treatment gap persists, as no more than 5% of patients with moderate to severe disease currently receive therapeutic intervention. P&F aims to close this gap by leveraging AVVie's technology to improve the quality of life for millions.
Strategic Integration of Innovation
Central to this acquisition is the AngelValve™ Augmentation System, an innovative transcatheter platform developed by AVVie to treat mitral valve disease. The company was founded by esteemed cardiac surgeon Prof. Werner Mohl, who envisioned a solution for patients with few or no viable treatment options. This technology represents a major step forward in minimally invasive structural heart interventions, promising new hope for many.
This strategic combination is expected to create powerful synergies, accelerating the path from innovation to clinical application. P&F will apply its global capabilities in product development, clinical trials, and regulatory affairs to AVVie's focused R&D infrastructure and intellectual property. This integrated approach is designed to shorten development timelines and expedite the delivery of the AngelValve™ system to the global market.
Leadership Vision for the Future
Katharina Kiss, CEO of P&F, emphasized that the acquisition reflects the company's unwavering commitment to advancing breakthrough structural heart therapies. She noted that combining AVVie's engineering excellence with P&F's proven expertise will deliver meaningful innovation for both physicians and patients worldwide. This transaction is another important step toward the company's vision of becoming a global leader in structural heart therapy.
This forward-looking perspective was shared by Siegfried Einhellig, COO and Head of R&D at P&F, who praised the fusion of outstanding engineering talent. He expressed his excitement about the potential to transform this cutting-edge innovation into a successful and widely available therapy. The collaboration aims to leverage combined strengths to establish new benchmarks in cardiovascular treatment and patient outcomes.
In conclusion, P&F's acquisition of AVVie represents a pivotal and strategic expansion of its cardiovascular product pipeline. By incorporating the AngelValve™ platform, the company not only strengthens its structural heart portfolio but also reinforces its mission to serve patients with unmet medical needs. Although the financial terms of the transaction were not disclosed, the move clearly positions P&F for sustained growth and leadership in the competitive medical technology industry.